Amgen, Inc. is a pioneering biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. The company markets its principal products mainly in the US, Europe and Canada. The company operates in one business segment: human therapeutics. Amgen markets human therapeutic products mainly in the areas of supportive cancer care, nephrology and inflammation. The company's major products include Neulasta (pegfilgrastim), Neupogen (filgrastim), Enbrel (etanercept), Xgeva/Prolia (denosumab), Aranesp (darbepoetin alfa), Epogen (Epoetin alfa), and Sensipar/Mimpara (cinacalcet). Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe. Neulasta is indicated to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients with non-myeloid malignancies.
The company markets Neupogen, a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), primarily in the US, Canada and Europe. Neupogen is used primarily in the indication for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever. The company markets Enbrel primarily in the US. It is used primarily in the indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis; chronic moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy; and active psoriatic arthritis. The rights to market and sell Enbrel outside the US and Canada are reserved to Pfizer.
In the US, Xgeva is used primarily in the indication for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in patients with bone metastases from solid tumors. It is not indicated for the prevention of SREs in patients with multiple myeloma. In Europe, Xgeva is used primarily in the indication for the prevention of SREs in adults with bone metastases from solid tumors. In the US, Prolia is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
In Europe, Prolia is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Aranesp, marketed primarily in Europe and the US, is indicated for the treatment of anemia associated with chronic kidney disease (CKD) (in both patients on dialysis and patients’ not on dialysis) and the treatment of anemia due to concomitant myelosuppressive chemotherapy in patients with non-myeloid malignancies. Epogen is marketed in the US for dialysis patients. It is marketed by Amgen for the indication to treat a lower-than-normal number of red blood cells (anemia) caused by CKD in patients on dialysis to lessen the need for red blood cell transfusions. The company markets cinacalcet primarily in the US and as Mimpara primarily in Europe. It is used primarily in the indication for the treatment of secondary hyperparathyroidism in CKD patients on dialysis.
The company markets several other products including Kyprolis (marketed by Onyx, an Amgen subsidiary), Nplate (romiplostim), Vectibix (panitumumab) and Blincyto (blinatumomab). In addition to the marketed products, Amgen has various product candidates in mid- to late-stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular, neuroscience and general medicine. Geographically, the US, Amgen, Inc.'s largest geographical market, accounted for 79.7% of the total revenues in FY2016. Revenues from the US reached $18,326 million in FY2016, an increase of 6.8% over FY2015. Rest of the World (ROW) accounted for 20.3% of the total revenues in FY2016. Revenues from ROW reached $4,665 million in FY2016, an increase of 3.8% over FY2015.
Scope of the Report
- About the Company - Historical Details, Current Ownership Structure and basic overview of Amgen, Inc. in terms of revenue, net income, and operating income.
- Financials - Details about Amgen, Inc. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
- Company SWOT Analysis - Outlines Amgen, Inc.’s strengths, weaknesses, and opportunities and threats facing the company.
- Recent Developments - Showcases Amgen, Inc.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
- Strategic Evaluation - Provides an overview of Amgen, Inc.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
- What domain does Amgen, Inc. operate and what are key points about it?
- What is the product / service portfolio of Amgen, Inc.?
- How has Amgen, Inc. performed financially from the 2013?
- How does Amgen, Inc. rank among its peers in terms of revenue and market share?
- What are Amgen, Inc. strengths and weaknesses and what opportunities and threats does it face?
- What are Amgen, Inc.’s main growth strategies and how successful has the company been at implementing them?
- What is the in-house technical capability of Amgen, Inc.? Where does it procure / outsource it?
Reasons to buy
- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
- 12 hour delivery time fulfilling your urgent requests as per your requirement
- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
7.1.1 Industry Snapshot
7.1.2 IT Spend
7.1.3 Key Information Technology Trends
7.2.1 IT Overview
7.2.2 Key IT Technologies
7.2.3 Recent IT Initiatives
7.2.4 IT Outsourcing Engagements
7.2.5 Key IT Management
7.2.6 CIO/CTO Profile
- About Us
- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years